MEDX.TO
Global X Equal Weight Global Healthcare Index ETF
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 2.7 M
ASSETS UNDER MGMT
40 bp
EXPENSES
Fund Basics
| Inception date | Apr 30, 2025 |
| Regulation | |
| Fund Website | link... |
| Distributions | |
| Currency | CAD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| NOVO-NORDISK A/S-SPONS ADR | 6.3 % |
| ELI LILLY & CO | 5.5 % |
| MERCK & CO. INC. | 5.2 % |
| VERTEX PHARMACEUTICALS INC | 5.2 % |
| ASTRAZENECA PLC | 5.2 % |
| BRISTOL-MYERS SQUIBB CO | 5.1 % |
| JOHNSON & JOHNSON | 5.1 % |
| PFIZER INC | 5.1 % |
| GSK PLC ADR | 5.1 % |
| NOVARTIS AG | 5.1 % |
Constituent Breakdown
| Number of holdings | 22 |
| Herfindahl-Hirschman Index | 500 |
| Wgt avg mkt cap (mns) | $235,080 |
| Large cap (>$10bn) | 89.7% |
| Mid cap ($2-10bn) | 0.0% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 100.0% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 76.5 % |
 |
DENMARK | 7.0 % |
 |
BRITAIN | 5.7 % |
 |
SWITZERLAND | 5.7 % |
 |
IRELAND | 5.1 % |
Historical Performance
Standardized Performance (as of 05/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -5.9% | 6.0% | -- | -- | -- | -- | -- | 4.7% |
| Dividend Yield | 0.2% | 1.7% | -- | -- | -- | -- | -- | 1.5% |
| Total Returns | -5.8% | 7.7% | -- | -- | -- | -- | -- | 6.2% | Ann. Volatility | 16.1% | 14.1% | -- | -- | -- | -- | -- | 14.4% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.16 | 2% |
| MSCI EAFE | 0.16 | 3% |
| MSCI Emg Mkts | 0.07 | 1% |
Liquidity Measures
| Avg. volume (000) | 0 |
| ADV traded (mns) | $0 |
| Turnover | 0.0% |
| Avg. Bid/Ask (% of price) | 0.00% |
Technical Indicators
| 30d moving avg. (EMA) | $20.93 |
| Relative strength (RSI) | 46 |
| MACD/Signal | -0.14/-0.23 |
| Bollinger Bands (Upper/Lower) | $21.20/$20.16 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. MEDX.TO |
Expenses vs. MEDX.TO |
ALTAR Score™ vs. MEDX.TO |
|---|---|---|---|---|
| LMAX.TO | Hamilton Healthcare YIELD MAXIMIZER TM ETF | 72.1% | +25 bp | -0.5% |
| HHL.TO | Harvest Healthcare Leaders Income ETF | 66.1% | +45 bp | -1.0% |
| MHCD.TO | Middlefield Healthcare Dividend ETF | 56.1% | +45 bp | -2.2% |
| HIG.TO | Brompton Global Healthcare Income & Growth ETF | 48.1% | +35 bp | -0.7% |
| TDOC.TO | TD Global Healthcare Leaders Index ETF | 34.1% | -5 bp | -0.5% |
| ZUH.TO | BMO Equal Weight US Health Care Hedged to CAD Index ETF | 18.1% | -5 bp | -2.0% |
| ZHU.TO | BMO Equal Weight US Health Care Index ETF | 17.6% | -5 bp | -2.3% |
| XEXP.TO | iShares Exponential Technologies Index ETF | 17.2% | -1 bp | -3.5% |
| XHD.TO | iShares U.S. High Dividend Equity Index ETF (CAD-Hedged) | 15.6% | -7 bp | -1.3% |
| XHU.TO | iShares U.S. High Dividend Equity Index ETF | 15.4% | -6 bp | -1.4% |
Risk and Returns: MEDX.TO vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (CAD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 6/18/2026
Peer Group Comparison
Sample data. Subscribe for access.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
7.8%
ALTAR SCORE™
91st
PERCENTILE
SPECULATIVE
ETFRC RATING
There are 731 funds in the Global Equity category with an average
ALTAR Score™ of 4.3% and a standard deviation
of 2.6%. MEDX.TO's ALTAR Score™ is approximately 1.3 standard
deviations above the category average. This places MEDX.TO in the 91st percentile
among funds in the category.
Sell-Side Consensus
$25.06
PRICE TARGET
+17.0%
UPSIDE